The US Food and Drug Administration has approved ... "Today's approval offers adults with obesity or overweight a beneficial new treatment option to incorporate into a weight management program ...
People with obesity who took the highest dose of the drug lost 21 percent of their total body weight, according to a randomized-controlled trial published in the New England Journal of Medicine.
Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new ... obesity, but is sufficiently encouraged by early-stage clinical data to kick off a phase 2 programme for the drug ...
an oncologist at Memorial Sloan Kettering Cancer Center in New York City. Iyengar researches the relationship between obesity and cancer. “I foresee that this class of drugs will revolutionize ...
The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans with Medicare and Medicaid, according to the White House.